MEI Pharma, Inc.
3611 Valley Centre Drive, Suite #500
About MEI Pharma, Inc.
MEI Pharma is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's portfolio of drug candidates includes Pracinostat, a potential best-in-class, oral HDAC inhibitor currently in Phase II clinical studies for advanced hematologic diseases. The Company is also developing ME-344, a novel mitochondrial inhibitor that has shown evidence of clinical activity in refractory solid tumors, and ME-401 (formerly PWT143), a highly selective, oral PI3K delta inhibitor. For more information, please visit www.meipharma.com.
CEO: Daniel Gold, PhD
Please click here for clinical trial information.
Please click here for Mei Pharma job opportunities.
289 articles with MEI Pharma, Inc.
Helsinn And MEI Pharma Announce First Patient Dosed In Pivotal Phase III Study Of Pracinostat And Azacitidine In Acute Myeloid Leukemia
Helsinn And MEI Pharma Announce First Patient Dosed In Phase II Dose-Optimization Study Of Pracinostat And Azacitidine In Myelodysplastic Syndrome
Helsinn And MEI Pharma Report Correlation Between Mutations In DNA Methylation Pathway And Clinical Response In Phase II Study Of Pracinostat And Azacitidine In Acute Myeloid Leukemia
MEI Pharma Announces Pre-Specified Response Rate Exceeded In Dose-Escalation Study Of ME-401 In Chronic Lymphocytic Leukemia And Follicular Lymphoma
Helsinn And MEI Pharma Report Prolongation Of Survival Results From Phase 2 Clinical Study Of Pracinostat And Azacitidine In Acute Myeloid Leukemia
Helsinn And MEI Pharma Announce Long-Term Survival And Response Data From Phase II Clinical Study Of Pracinostat In Acute Myeloid Leukemia Accepted For Oral Presentation At Upcoming American Society of Hematology Annual Meeting
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) To Present At Needham Healthcare Conference